About Spruce Biosciences
Spruce Biosciences is a publicly listed company based in San Francisco (United States) founded in 2014 by Alexis Howerton. Rare HPA axis diseases are targeted by Spruce Biosciences therapeutics. Spruce Biosciences has raised $108 million across 3 funding rounds from investors including Citadel, Abingworth and 5AM Ventures. The company has 15 employees. Its chief executive, as recorded, is Richard King. Spruce Biosciences offers products and services including TA-ERT. Its focus areas include Life Sciences, Rare Diseases, Drugs and Endocrine Diseases. Its legal entity is SPRUCE BIOSCIENCES, INC. Its competitors include MBX Biosciences, Spruce and Sigilon; 3 of its 3 listed competitors have raised funding.
Company details
Spruce Biosciences was founded in 2014 and is based in San Francisco, United States. As a clinical-stage biopharmaceutical company, small molecule therapeutics are developed for rare endocrine disorders impacting the hypothalamic-pituitary-adrenal axis. The lead program, SPR001, addresses congenital adrenal hyperplasia in both chronic and acute forms and is advancing through Phase 2 clinical trials. The mechanism of action for this oral candidate remains under investigation.
- Headquarters San Francisco, United States
- Employees 15
- Founders Alexis Howerton
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website sprucebiosciences.com
- Social LinkedIn X Facebook
- Legal Name Spruce Biosciences, Inc
- Total Equity Funding$108M (USD)
in 3 rounds
- Latest Funding Round$53.62M (USD), Post-IPO
Feb 2023
- InvestorsCitadel
& 10 more
- Employee Count15
Products & Services of Spruce Biosciences
Spruce Biosciences offers a comprehensive portfolio of products and services, including TA-ERT.
Targets Mucopolysaccharidosis Type IIIB to improve neurological outcomes.
Funding Insights of Spruce Biosciences
Spruce Biosciences has successfully raised a total of $108M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $53.62 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108M
- Total Rounds 3
- Last Round Post-IPO — $53.62M
- First Round $20M
(Jun 2016)
- Investors Count 11
All 3 funding rounds of Spruce Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $53.62M | Post-IPO | – | – | |
| Feb 2020 | $88M | Series B | – | Omega Funds, Abingworth | |
| Jun 2016 | $20M | Series A | – | Novo Holdings |
11 investors in total: 11 institutional.
Investors in Spruce Biosciences
Spruce Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Abingworth and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
| healthcap.eu | ||||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| rivervest.com | ||||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | sandscapitalventures.com | Arlington, United States | ||
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States |
Investor details for Spruce Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Spruce Biosciences
25 people are tracked at Spruce Biosciences (9 in leadership, 9 in board & advisors, 7 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Alexis Howerton | Founder | Leadership |
Richard King | CEO | Leadership |
Teri F. | Director | Leadership |
Javier Szwarcberg | CEO | Leadership |
Samir Gharib | President & CFO | Leadership |
Anna Fath | Director Key Customer Engagement & Program Management | Leadership |
Ashokraj Rajagopal | Senior Director | Leadership |
Saba Sile | VP Clinical Development | Leadership |
Tony Szeto | Senior Director, Finance | Leadership |
Bali Muralidhar | Director | Board & advisors |
Percival Barretto-Ko | Independent Director | Board & advisors |
Niall O’Donnell | Director | Board & advisors |
Camilla V. Simpson | Director | Board & advisors |
Tiba Aynechi | Independent Director | Board & advisors |
Dan Spiegelman | Director | Board & advisors |
Mike Grey | Executive Chairman | Board & advisors |
Kirk Ways | Independent Director | Board & advisors |
Dina Chaya | Board Director | Board & advisors |
Ivona Zielinska | Senior Clinical Trial Manager | Team |
Mo Noursalehi | SVP, Biometrics | Team |
5 more people are available in the full profile.
Complete people profiles for Spruce Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Spruce Biosciences
Spruce Biosciences is a publicly listed company on the NASDAQ with ticker symbol SPRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Oct 2020
- Listed onNASDAQ: SPRB
- Listed entitySpruce Biosciences, Inc.
- Exchange sectorHealth technology
Timeline of Spruce Biosciences
4 dated milestones of Spruce Biosciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Spruce Biosciences is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $53.6M.
Competitors of Spruce Biosciences
Spruce Biosciences has 3 listed competitors in our database, 3 of them funded. They include MBX Biosciences, Spruce and Sigilon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. | |
| spruce.co | 2016 | New York, United States | $109.08M | 169 | Spruce is engaged in providing real estate closing services. | |
| sigilon.com | 2015 | Cambridge, United States | $103.8M | 66 | Therapeutics for chronic diseases are developed via cell engineering platforms. |
Detailed competitors of Spruce Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Spruce Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Spruce Biosciences
Complete news archive for Spruce Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spruce Biosciences
Spruce Biosciences was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Spruce Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Richard King is the CEO of Spruce Biosciences, as recorded in our data.
Spruce Biosciences is a funded company, having raised a total of $108M across 3 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Jun 2016.
Spruce Biosciences has 15 employees.
Spruce Biosciences was founded in 2014 and is based in San Francisco, United States. As a clinical-stage biopharmaceutical company, small molecule therapeutics are developed for rare endocrine disorders impacting the hypothalamic-pituitary-adrenal axis. The lead program, SPR001, addresses congenital adrenal hyperplasia in both chronic and acute forms and is advancing through Phase 2 clinical trials. The mechanism of action for this oral candidate remains under investigation.
Spruce Biosciences's top competitors include MBX Biosciences, Spruce and Sigilon.
Spruce Biosciences offers TA-ERT.
Yes, Spruce Biosciences is publicly traded on NASDAQ under the ticker symbol SPRB.
Spruce Biosciences has 11 investors. Key investors include Citadel, Abingworth, 5AM Ventures, Healthcap, and Novo Holdings.
Spruce Biosciences operates through Spruce Biosciences, Inc.